◼ Archived
Business
With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
Alkermes reports positive Phase Ib trial data for ALKS 7290, sparking significant market and medical interest.
3 trends tracked about this subject — the full history, oldest to newest below.
Alkermes reports positive Phase Ib trial data for ALKS 7290, sparking significant market and medical interest.
Salesforce shares face a historic decline, marking a record 14-day losing streak as market analysts scrutinize the company's unit economics.
Micron Technology faces heightened market focus as stock performance surges ahead of its upcoming third-quarter financial results.